Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07341997

Environmental Factors Associated With Peripheral Neuropathies in French Guiana

Peripheral neuropathies (PN) affect 1% of the global population, particularly the elderly. About 20-30% of cases remain unexplained. In French Guiana, we hypothesize that factors like neurotoxic traditional plant remedies, arboviral disease outbreaks, and mercury exposure from illegal gold mining may contribute to PN. The study aims to assess the association between PN and exposure to arboviral infections, heavy metals, and plant consumption in French Guiana.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier de Cayenne, Cayenne, French Guiana

Loading trial locations.

About this study

Peripheral neuropathies (PN) affect 1% of the global population, with higher prevalence in the elderly. They lead to gait disorders and chronic pain, severely impacting quality of life. Despite thorough investigations, 20-30% of cases have no identified cause. In French Guiana, unique factors may contribute to these neuropathies, including the use of potentially neurotoxic traditional plant remedies and outbreaks of arboviral diseases, which can complicate conditions like Guillain-Barré syndrome. Additionally, illegal gold mining exposes residents to mercury, both directly and through environmental contamination. We hypothesize that these local factors might explain the unidentified cases of PN and exacerbate neuropathies in patients with pre-existing nerve vulnerability, such as diabetic neuropathy.

This is a prospective multicenter case-control study being conducted in hospitals in Cayenne and Saint-Laurent du Maroni. At the inclusion visit, blood samples will be taken to assess arbovirus serology, particularly for Zika, Chikungunya and Dengue, as well as to measure levels of heavy metals, including mercury and lead. In addition, urine and hair samples will be taken to analyze these heavy metals. Participants will also fill in a questionnaire about their plant consumption.

They will not be followed as part of the research.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For the Case group: patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy
  • For the Control group: patients hospitalized or consulting at the hospitals in Cayenne and Saint-Laurent du Maroni, without peripheral neuropathy.

Exclusion criteria

  • For the Case and Control groups: patients under the age of 18, those who object to participation and those who are unable to complete the questionnaire.

Treatment and study plan

Case Group

Other

Patients diagnosed with diabetic peripheral neuropathy or chronic idiopathic axonal polyneuropathy.

Primary outcomes

  1. Comparison of exposure rates among cases and controls

    Time frame: At inclusion

    The primary endpoint will be the comparison of rates of exposure to arboviruses, heavy metals and consumption of potentially neurotoxic plants in cases and controls.

    The heavy metals assay and the questionnaire will be carried out at the inclusion visit.

Secondary outcomes

  1. Genetic mutations indentification

    Time frame: At inclusion

    Secondary endpoint will be identification of genetic mutations responsible for peripheral neuropathy

  2. Peripheral Nerve Disability (PND) determination

    Time frame: At inclusion

    Secondary endpoint will be determination of Peripheral Nerve Disability (PND)

Study contacts

Contact information is provided by the study sponsor or research team.

Nathalie DESCHAMPS, Principal Investigator

CONTACT

[email protected]

+594 594 397 317

Vincent De Paul SENEKIAN, Principal Investigator

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Admin CIC

Other

Registry information

Acronym: YANANER

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.